Memigmin

Memantine, the active ingredient in Memigmin, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is employed in the symptomatic treatment of moderate to severe Alzheimer’s disease, helping to improve cognition and functional abilities in affected patients.

GNH USA supplies Memigmin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Clients benefit from reliable supply chains, competitive pricing, and responsive technical support throughout the ordering process.

Memigmin (memantine) acts on the glutamatergic pathway and is indicated for the following Alzheimer’s disease related conditions: - Alzheimer’s disease (moderate to severe): improves cognitive function and daily living activities. - Alzheimer’s disease (behavioral symptoms): reduces agitation and aggression associated with the disease. - Alzheimer’s disease (functional decline): helps slow the progression of functional impairment.

Memigmin may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue

Serious or Rare Side Effects: - Seizures - Severe skin reactions such as Stevens‑Johnson syndrome - Neuropsychiatric events including hallucinations or severe confusion

When prescribing Memigmin, several safety considerations should be observed. - Dose titration: start low and increase gradually as tolerated. - Renal impairment: adjust dose in patients with reduced kidney function. - History of seizures: monitor closely for increased seizure risk. - Concurrent use with other NMDA antagonists: avoid combination therapy. - Pregnancy and lactation: use only if potential benefit justifies risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Memigmin can interact with other medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase memantine levels. - Combination with other NMDA antagonists (e.g., amantadine) may enhance neurotoxicity. - High‑dose aspirin or NSAIDs may increase risk of gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - Use with anticholinergic agents may reduce therapeutic benefit. - Concurrent use with drugs that lower seizure threshold (e.g., bupropion) requires monitoring. - Co‑administration with diuretics may affect renal clearance of memantine.